Physician profile
William E Snell
NPI 1013932003
$1,904.33
in general payments reported to CMS, 2019-2025
30 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $473 · 2021: $628 · 2022: $108 · 2023: $119 · 2024: $130 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $385.27 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $262.64 | 2020-2022 | |
| Pfizer INC. | $225.69 | 2019-2021 | |
| Novo Nordisk INC | $189.28 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $86.93 | 2020-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $86.79 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $70.73 | 2021-2022 | |
| Amgen INC. | $65.79 | 2019-2020 | |
| Eisai INC. | $64.04 | 2020 | |
| Galt Pharmaceuticals, LLC | $45.93 | 2023 | Orphengesic Forte |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.68 | 2021-2022 | |
| Abbvie INC. | $42.76 | 2021-2022 | |
| Astellas Pharma US INC | $38.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.38 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $34.97 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.85 | 2024 | Venaseal |
| Kyowa Kirin, INC. | $20.66 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $18.87 | 2021 | |
| Abbott Laboratories | $18.17 | 2021 | |
| Dexcom, INC. | $17.24 | 2021 | |
| Boston Scientific Corporation | $16.48 | 2019 | |
| Phadia US INC. | $14.51 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.99 | 2022 | |
| Cmp Pharma, INC. | $13.77 | 2023 | Carospir, Norliqva, Tadliq |
| Teva Pharmaceuticals USA, INC. | $12.95 | 2019 | |
| Smith+Nephew, INC. | $12.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2022 | |
| Allergan, INC. | $11.15 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.